Sort
172,184 grants matching “inflammation”
Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD
$999,998Dominick Auci · Therapyx, Inc. · R44 · FY2019 · AI
Diagnostic array for aseptic encephalitis
$999,998Darrell P Chandler · Akonni Biosystems, Inc. · R44 · FY2014 · AI
Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD
$999,998Thomas F Conway · Therapyx, Inc. · R44 · FY2011 · AI
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
$999,997Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2024 · AI
Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
$999,997Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2025 · AI
Micronized salsalate in a parenteral formulation is a safe and effective analgesic for acute postoperative pain management
$999,994Joel Steven Ross · Rh Nanopharmacueticals L.L.C. · R44 · FY2021 · NS
Antimicrobial Treatment to Combat Wound Biofilm
$999,993Jennifer Ann Neff · Allvivo Vascular, Inc. · R44 · FY2024 · AI
CMC of Peptide Formulation for the Treatment of ARDS
$999,993Gerardo M. Castillo · Pharmain Corporation · R44 · FY2022 · HL
Preclinical evaluation of a novel small molecule STAT inhibitor
$999,993Robert Sons · Fannin Partners, Llc · R44 · FY2018 · AI
Targeting lipid rafts for treatment of asthma
$999,991Yakov Kogan · Raft Pharmaceuticals, Llc · R44 · FY2023 · AI
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
$999,989Neil A Fanger · Virtici, Llc · R44 · FY2025 · HL
Thyroid Cancer Aggressiveness in WTC Responders
$999,987Emanuela Taioli · Icahn School Of Medicine At Mount Sinai · U01 · FY2020 · OH
POLYGENIC PREDICTION OF PTSD TRAJECTORIES AND INFLAMMATION IN 9/11 RESPONDERS
$999,986Roman I Kotov · State University New York Stony Brook · U01 · FY2020 · OH
Antimicrobial Treatment to Combat Wound Biofilm
$999,985Jennifer Ann Neff · Allvivo Vascular, Inc. · R44 · FY2025 · AI
Novel biologic to treat chemotherapy-induced neuropathic pain
$999,967Yakov Kogan · Raft Pharmaceuticals, Llc · R44 · FY2022 · CA
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis
$999,953Abigail Pulsipher · Glycomira, Llc · R44 · FY2021 · AI
Novel Strategies to Clear Bacteria from the CF Lung
$999,919Saira Ahmad · Eldec Pharmaceuticals, Inc. · R44 · FY2022 · HL
A Prospective Study of T cell Immune-phenotype and Disease Outcome in Pulmonary Sarcoidosis
$999,912Brian P O'Connor · National Jewish Health · R01 · FY2020 · HL
Polygenic risk scores and health disparities: the role of blood cells immune response and evolutionary adaptation
$999,907Yun Li · Univ Of North Carolina Chapel Hill · U01 · FY2021 · HG
Clinical Utility of Endothelial Function in PAD
$999,902Boston Medical Center · R01 · FY2003 · HL
POLYGENIC PREDICTION OF PTSD TRAJECTORIES AND INFLAMMATION IN 9/11 RESPONDERS
$999,901Monika Aldona Waszczuk · State University New York Stony Brook · U01 · FY2019 · OH
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease
$999,898Edward Gomperts · Hillhurst Biopharmaceuticals, Inc. · R44 · FY2024 · HL
Improving Functioning in Peripheral Arterial Disease
$999,863Northwestern University · R01 · FY2003 · HL
ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung
$999,840Robert Tarran · Eldec Pharmaceuticals, Inc. · R42 · FY2021 · AI
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
$999,799Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2023 · HL